The FDA has refused to even review Innocoll's (INNL) new drug application for XARACOLL, the company's product candidate for the treatment of postsurgical pain, and has issued a Refusal to File letter.
from RTT - Biotech http://ift.tt/2iLcxsQ
via IFTTT
No comments:
Post a Comment